Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial
Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial. JAMA 2014; 311: 1870-82.
Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2531-40.
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014; 63: 2541-8.
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J 2016; 173: 94-101.
ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: Suppl 2: S1-S45.
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18, 144 patients post ACS
abstract
Giugliano RP, Cannon C, Blazing M, et al. Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18, 144 patients post ACS. J Am Coll Cardiol 2015; 65: Suppl: A4. abstract.
Effect of evolocumab on progression of coronary disease in statin-Treated patients: The GLAGOV randomized clinical trial
Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-Treated patients: The GLAGOV randomized clinical trial. JAMA 2016; 316: 2373-84.
ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016; 68: 92-125.
European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk
October Epub ahead of print
Landmesser U, John Chapman M, Farnier M, et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2016 October 27 (Epub ahead of print).
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Comparing and contrasting guidance across the Atlantic
Epub ahead of print
Sabatine MS. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J 2017 January 21 (Epub ahead of print).
Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-Aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-Aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia-report of the Program on the Surgical Control of the Hyperlipidemias (POSCH
Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia-report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323: 946-55.
Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170, 000 participants in 26 randomised trials
The Cholesterol Treatment Trialists' Collaboration
The Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
Scandinavian Simvastatin Survival Study Group
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-Analysis
Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-Analysis. JAMA 2016; 316: 1289-97.
Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes
Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 2016; 375: 2144-53.
Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-Analysis of randomised statin trials. Lancet 2010; 375: 735-42.
Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-Analysis
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-Analysis. JAMA 2011; 305: 2556-64.
Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. Press release from Pfizer, New York, November 1, 2016 (http://www .pfizer .com/news/press-release/press-release-detail/Pfizer-discontinues-global-development-of-bococizumab-its-investigational-pcsk9-inhibitor).
Long-Term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years from the open-label OSLER-1 extension study
Epub ahead of print
Koren MJ, Sabatine MS, Giugliano RP, et al. Long-Term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol 2017 March 14 (Epub ahead of print).